Back to Search Start Over

Cross-reactive CD4 + T cells enhance SARS-CoV-2 immune responses upon infection and vaccination.

Authors :
Loyal L
Braun J
Henze L
Kruse B
Dingeldey M
Reimer U
Kern F
Schwarz T
Mangold M
Unger C
Dörfler F
Kadler S
Rosowski J
Gürcan K
Uyar-Aydin Z
Frentsch M
Kurth F
Schnatbaum K
Eckey M
Hippenstiel S
Hocke A
Müller MA
Sawitzki B
Miltenyi S
Paul F
Mall MA
Wenschuh H
Voigt S
Drosten C
Lauster R
Lachman N
Sander LE
Corman VM
Röhmel J
Meyer-Arndt L
Thiel A
Giesecke-Thiel C
Source :
Science (New York, N.Y.) [Science] 2021 Oct 08; Vol. 374 (6564), pp. eabh1823. Date of Electronic Publication: 2021 Oct 08.
Publication Year :
2021

Abstract

The functional relevance of preexisting cross-immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a subject of intense debate. Here, we show that human endemic coronavirus (HCoV)–reactive and SARS-CoV-2–cross-reactive CD4 <superscript>+</superscript> T cells are ubiquitous but decrease with age. We identified a universal immunodominant coronavirus-specific spike peptide (S816-830) and demonstrate that preexisting spike- and S816-830–reactive T cells were recruited into immune responses to SARS-CoV-2 infection and their frequency correlated with anti–SARS-CoV-2-S1-IgG antibodies. Spike–cross-reactive T cells were also activated after primary BNT162b2 COVID-19 messenger RNA vaccination and displayed kinetics similar to those of secondary immune responses. Our results highlight the functional contribution of preexisting spike–cross-reactive T cells in SARS-CoV-2 infection and vaccination. Cross-reactive immunity may account for the unexpectedly rapid induction of immunity after primary SARS-CoV-2 immunization and the high rate of asymptomatic or mild COVID-19 disease courses.

Details

Language :
English
ISSN :
1095-9203
Volume :
374
Issue :
6564
Database :
MEDLINE
Journal :
Science (New York, N.Y.)
Publication Type :
Academic Journal
Accession number :
34465633
Full Text :
https://doi.org/10.1126/science.abh1823